the new governments focus on reducing costs (everywhere) should stimulate more generics sales... With Nasrats background in generics this could be a powerful growth driver on its own IMO, and possibly a sustainable business... You could make an argument that you get all the proprietary pharma products for free... nice...
Nope. Just one of the latest generics filings launched and those R&D costs are covered and some. Being that the first was filed in August, we should see an approval around that time this year.
News 
Market Data 
Discover 
